40 results about "Hypnotic drugs" patented technology

Pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs or their pharmaceutically acceptable salts, solvates, enantiomers or mixtures and processes for preparing the same. The invention also includes immediate release and extended release pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs, useful for sleep induction and sleep maintenance.

The invention relates to a sleep-improving health food composition which comprises the following raw materials by weight: 8 to 40 parts of gamma-aminobutyric acid powder, 0.8 to 8 parts of a Chinese magnoliavine extract, 5 to 20 parts of a calcium-containing compound, 5 to 20 parts of a magnesium-containing compound and 0.01 to 1 part of vitamin B6. The invention further provides a sleep-improving preparation and a preparation method thereof. The sleep-improving health food composition and the sleep-improving preparation use gamma-aminobutyric acid powder, the Chinese magnoliavine extract, the calcium-containing compound, the magnesium-containing compound and the vitamin B6 as main components, do not contain the component of hypnotics, can effectively soothe emotion of a stressed population and people with bad sleep and improve sleep quality.

A closed loop method and apparatus for controlling the administration of an hypnotic drug to a patient. Electroencephalographic (EEG) signal data is obtained from the patient. At least one measure of the complexity of the EEG signal data is derived from the data. The complexity measure may comprise the entropy of the EEG signal data. The EEG signal data complexity measure is used as the feedback signal in a control loop for an anesthetic delivery unit to control hypnotic drug administration to the patient in a manner that provides the desired hypnotic level in the patient. An EEG signal complexity measure obtained from the cerebral activity of the patient can be advantageously used in conjunction with a measure of patient electromyographic (EMG) activity to improve the response time of hypnotic level determination and of the feedback control of drug administration. A pharmacological transfer function may be used, along with pharmacokinetic and pharmacodynamic models.

The present invention consists of an apparatus for the on-line identification of drug effect using drug interactions and physiologic signals, in particular the interaction between anaesthetics and analgesics combined with the electroencephalogram for precise assessment of the level of consciousness in awake, sedated and anaesthetised patients. In a preferred embodiment the apparatus comprises: two infusion devices, for example syring pumps, which are connected to the patient (1) adapted to deliver hypnotics (2) and analgesics (3). The infusion data from the pumps are fed into an interaction model (5); an interaction model characterized by a Neural Network which is adapted to estimate the parameters of the model online and in real-time for drug interaction between anaesthetics and an analgesics, an EEG instrumentation amplifier; a processing unit adapted to calculate an EEG index of the level of consciousness (ELC); a fuzzy logic reasoner adapted to merge extracted EEG parameters into an index.

The invention relates to the field of medicine and discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and new biological activity of part of a flavonoid mono compound extracted from Murraya paniculata leaves, namely discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and the use of part of a flavonoid mono compound extracted from Murraya paniculata leaves in preparation of sedative and hypnotic drugs, anxiolytic drugs, anticonvulsive drugs or antimanic drugs, in particular to the use in preparation of sedative and hypnotic drugs.

The invention relates to a method and an apparatus for monitoring the autonomous nervous system of a sedated patient. According to the method, skin conductance is measured through a time interval. Average skin conductance values and the number of fluctuation peaks are in the interval are calculated and analyzed, and an indication is given of the state of pain / discomfort in the patient as well as the state of awakening in the patient. The invention is particularly applicable for use with anaesthetized or artificially ventilated patents, as separate output signals are automatically provided, indicating the need for analgesics and hypnotics, respectively.

The certified doctor in United States, use pentobabital sodium as the hypnotic to refrain central nervous system. Pentobabital sodium can be patience to the body after two weeks, and the effect decrease half, and have lingering effects and remain effects. The making method and pharmacological activity about the six kinds of plants and sodium pentobarbital's synergistic action wares are gaven patent. Under the cautious and strict conditions, extract the plant ingredients, absorb them by WLD resin, separate and purify them, and use the finger mark atlas quantity to make sure that the end product poise and stabilize. Six plant compound wares have sedate, hypnotize and synergy pentobabital sodium, anti-penfourzopol. The clinical use proved the reliability. It is safe and compensatory to the pentobabital sodium. It solves the hypnotic's tolerance and addiction. It solves the problem, which is expected to conquer for a long time.

The present invention provides pharmaceutical compositions comprising a flumazenil, and methods of alleviating or counteracting residual effects (e.g. drowsiness) associated with the administration of sleep / hypnotic drugs or alleviating effects of alcohol intoxication, using self administration modes of delivery.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

The invention relates to a methylphenidatefrozen dry powder preparation for injection and a preparation process thereof; the preparation takes the salt of the methylphenidatefrozen as drug constituents and forms the drug composite by mixing acceptable accessories pharmaceutically; the preparation method is that: the salt of the methylphenidatefrozen is taken as raw material, the accessories with specific kinds and proportion are added, and the dry powder preparation for intravenous injection is prepared and developed by adopting the illustrative technological measures. The dry powder preparation is used for treating attention deficiency hyperkinetic disorder (hyperkinetic syndrome of children and mild brain functional maladjustment), and eliminating somnolence, lassitude and respiratory depression caused by soporifics.

Disclosed is a use of flavones derivatives and flavanone derivatives in preparation of sedative and hypnotic drugs.

An orally disintegrating tablet of sedative-hypnotic medicine and a preparation method for the same are disclosed. The invention relates to an orally disintegrating tablet of sedative-hypnotic medicine as well as a prescription and a process for preparing the orally disintegrating tablet of sedative-hypnotic medicine by a freeze-drying method. The orally disintegrating tablet of sedative-hypnotic medicine disclosed by the invention is prepared from main medicines and pharmaceutical excipients, without the need of water while being taken, capable of being rapidly disintegrated in mouth, and suitable for the medication of the patients with difficulty in swallowing, such as the old and children; simultaneously, the orally disintegrating tablet of sedative-hypnotic medicine is suitable for the medication in a condition that water source is not easy to obtain during travelling; moreover, the orally disintegrating tablet of sedative-hypnotic medicine can avoid the influence on sleep due to micturition desire because of no need of water while being taken, thus exerting curative effect better; and the orally disintegrating tablet of sedative-hypnotic medicine disclosed by the invention has better compliance and therapeutic effect in the case that the patients with neurological disease are passive or incoordinate and for the old patients with insomnia compared with other forms, and can obviously reduce the side effects of the sedative-hypnotic medicine. Additionally, the invention further relates to a preparation method for an orally disintegrating tablet of sedative-hypnotic medicine.

The invention discloses a pharmaceutical composition with sedative and hypnotic effects. The pharmaceutical composition is a preparation prepared from the following raw material drugs in parts by weight: 4 to 6 parts of aquilariae lignum resinatum leaf, 2 to 3 parts of lucid ganoderma and 2 to 3 parts of fiveleaf gynostemma herb. A pharmacological experiment shows that the pharmaceutical composition has good sedative and hypnotic effects and is capable of obviously shortening the fall-asleep time, prolonging the sleep time and reducing automatic action, and a new selection is provided for clinically using sedative and hypnotic drugs.

The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may be achieved by either varying the concentration of fluorescein, or by combining fluorescein with another dye. The invention is also directed to methods involving the use of said pharmaceutical compositions.

The invention discloses a hypnotic comprising, by mass, 1-5 parts of clove, 1-4 parts of papaya, 4-8 parts of dragon teeth, 3-9 parts of greenish lily bulb, 2-5 parts of creeping liriope, 1-3 parts of villous amonmum fruit, 1-2 parts of east Asian tree fern, 1-3 parts of tsao-ko amomum fruit, 2-4 parts of medicinal fatheadtree stem and bark, 1-5 parts of giant gecko, 1-2 parts of sandalwood, 2-3 parts of Chinese knotweed herb, 2-5 parts of cluster mallow fruit, 2-4 parts of buerger pipewort head, 1-6 parts of dried bitter gourd, and 3-8 parts of dogbane leaf. The hypnotic provided by the invention has the functions of convulsion relieving, tranquilizing, heat clearing, restlessness relieving, yin nourishing, body fluid generating, lung moistening, heat-fever clearing, dampness eliminating, coldness relieving, phlegm expelling, malaria stopping, and digestion promoting.

The invention belongs to the field of traditional Chinese medicine pharmaceutical manufacturing, and particularly relates to a preparation method of single-medicine spine date seed extract and application of the spine date seed extract in calming and hypnosis drugs. The preparation method is simple in technology, low in cost and suitable for industrial preparation. The method for preparing the spine date seed extract comprises the following steps that 1, the medicinal material of spine date seeds is weighed; 2, reflux extraction is conducted twice through ethyl alcohol with the weight being 10 times that of the medicinal material and the volume concentration of 30%-50%, and reflux extraction is conducted for 0.5-2 h each time; 3, an extracted solution is concentrated to obtain dry extract or is freeze-dried to obtain the spine date seed extract. The invention further provides the application of the spine date seed extract in preparation of the calming and hypnosis drugs. It is indicated through pharmacology experiments that the hypnotic effect is significant when extraction is conducted through the ethyl alcohol of 30% and has no obvious difference compared with that of water extract.

An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage forms and comprises preferably 600 to 2400 mg of a ratio of 4-10 parts (wt) dried plant material to 1 part (wt) aqueous alcohol (50-90 vol % ethanol) extract that is equivalent to 3-12 grams of the dried herb top of California poppy and contain at least 0.8 wt % isoquinoline alkaloids. The composition may further comprise isoquinoline alkaloids whose composition contains Californidine, Escholtzine and Protopine. California poppy can also be used as a therapy for managing people that have sleep and dream disorders such as Post Traumatic Stress syndrome and similar conditions that induce nightmares as well as people using tranquilizer, antidepressant, antipsychotic, sedative, hypnotic and analgesic drugs.

The invention provides a preparation method of a traditional Chinese medicine for treating blood stasis type insomnia and belongs to the technical field of preparation method of traditional Chinese medicines. At present, a sedative-hypnotic drug, an antianxiety agent or an antidepressant is commonly adopted to treat the blood stasis type insomnia, and has the defect that the toxic and side effect is serious. The technical scheme provided by the invention is as follows: the traditional Chinese medicine for treating the blood stasis type insomnia is prepared by soaking rosa chinensis, pseudo-ginseng, setose thistle, camellia japonica, field thistle, osbeckia chinensis, folium artemisiae argyi, cactus, hairyvein agrimony, rhizoma bletillae, furnace soil, crinis carbonisatus, rumex japonicas, marmor serpentinatum, radix boehmeriae, madder, common sage herb, hollyhock flower, eclipta, ossa draconis, albizia julibrissin, polygala tenuifolia, tuber fleeceflower stem, coral, semen boitae, poria with hostwood, gagea lutea, salvia miltiorrhiza and liquorice into water, then decocting for 3h by slow fire, and filtering to remove slag to obtain liquid medicine which is the traditional Chinese medicine for treating blood stasis type insomnia. The traditional Chinese medicine prepared by the method has the advantages that the toxic and side effect is low, the course of treatment is short and the curative ratio is high, and can be used for avoiding the adverse drug reaction caused by western medicines.

The invention, which relates to the field of health care product detection, provides a simultaneous detection method for illegally added medicines in a tranquilizing and allaying excitement health-care product. Specifically, the method for simultaneous determination of illegally added drugs such as benzodiazepines, barbital and atypical benzodiazepines hypnotics in tranquilizing and allaying excitement health-care products by ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS-MS) comprises the steps of extraction, purification, membrane filtration, tandem triple quadrupolemass spectrometry detection and establishment of a standard curve. The method is simple in steps, high in accuracy and good in reproducibility, can be used for qualitatively and quantitatively analyzing various illegally added medicines in the health care product at the same time, and has the advantage of rapid and high-throughput detection.

The invention is applicable to the technical field of fragrance products, and provides a fragrance spray for helping sleep and a preparation method and application thereof. The fragrance spray comprises the following components: herba selaginellae, caulis polygoni multiflori, herba lophatheri, herba mimosae pudica, radix valerianae and lotus plumule. The fragrance spray provided by the invention takes herbal traditional Chinese medicine extract essence as a main component, achieves the purpose of improving sleep by improving the sleep environment, has no toxicity, no harm and no side effects on a human body, overcomes the defects of drug accumulation, drug dependence, drug resistance and other side effects on the human body caused by oral administration of traditional hypnotic drugs, and also overcomes the inconvenience of decoction and administration of traditional Chinese medicines. At the same time, compared with products with sleep improvement, such as aromatherapy products, sachetsachets, medicine bags and medicine pillows on the market, the fragrance spray has the characteristics of no need of heating, no mildew and no breeding of microorganisms, and realizes the product characteristics of portability, convenient use, no side effects, safety, reliability and outstanding effect at home, in travel, in the field and the like.

The present invention provides a novel use of a Maydis stigma extract in prophylaxis, alleviation, or therapy of sleep disorder. A Maydis stigma extract has the effect of reducing sleep onset latency and increasing sleep duration, as high as or higher than the effect of ketamine or pentobarbital, which are conventionally used as soporifics. As a natural substance, the Maydis stigma extract does not cause side effects, such as cytotoxicity, resistance, or dependency, even when used for a long term.

The invention belongs to the field of compound drugs, relating to a new medicinal application of a compound genistein and derivatives thereof, in particular to the application of the genistein and the derivatives thereof in preparing hypnotic drugs and health products. The results of animal experiments for the genistein and the derivatives thereof show that the genistein and the derivatives thereof can cure insomnia by increasing non-rapid eyes movement sleeping time with an increase of about 80% in NREM sleep time within 6 hours after the animals being dosed. Especially, the NREM sleep time within 6 hours after the animals being dosed can be dosage-dependently increased. The genistein and the derivatives thereof have hypnotic activity and sleep quality improving effect, and can be used for preparing hypnotic drugs promoting sleep and drugs or health products improving sleep quality, especially suitable for treatment of sleep disorder in perimenopausal women.

The invention provides a hypnotic clock. The clock comprises a clock housing body, a clock device and a hypnotic device. The clock housing body is of a thin shell-type structure. Other devices are installed in the clock housing body. The clock device comprises a clock panel, a machine core, a clock switch and a cell and is used for achieving normal clock functions. The hypnotic device comprises ahypnotic switch, a control circuit, an audio selection button, a volume adjusting button, a display screen and a loudspeaker. After the hypnotic switch is pressed down, a user is capable of choosing favorite natural sound through the audio selection button. A display result is displayed on the display screen. By use of the volume adjusting button, the volume of the sound produced by the loudspeaker can be adjusted. The beneficial effects are that the clock is simple in structure, convenient to operate and highly reliable; and the clock is capable of waking up a person and helping the person tosleep by playing the natural sound, so the clock has two functions.

There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

The invention discloses a eucommia active monomer compound, the structural formula of which is shown in the specification. The invention also discloses a preparation method of the compound, a pharmaceutical composition containing the compound and pharmaceutical application of the compound. The active monomer compound is extracted from eucommia and can be extracted from eucommia bark, eucommia leaves, eucommia male flowers, eucommia seeds or whole eucommia plants. The extracted active monomer compound is 4-hydroxy-3-(2-hydroethyl)-1-cyclopentene-1,2-dimethanol, and experiments prove that the compound has obvious sedation, hypnogenesis, anti-convulsion and other effects as well as no side effect and dependence, and can be taken for a long time. The active monomer compound extracted from eucommia and the effects of the compound in the aspects of sedation, hypnogenesis, anti-convulsion and the like are provided in the invention, thereby providing a novel natural active substance for researching and developing novel health-care food and novel sedative-hypnotic drugs.